We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current RPHCF market cap is 4.67B. The company's latest EPS is JPY 135.6011 and P/E is 0.15.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 188.33B | 181.29B | 199.65B | 238.66B | 270.84B |
| Operating Income | 21.05B | 21.96B | 28.6B | 34.04B | 39.44B |
| Net Income | 15.41B | 16.74B | 21.02B | 26.38B | 30.94B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 215.3B | 225.79B | 274.63B | 309.68B | 346.18B |
| Total Liabilities | 75.27B | 69.18B | 90.79B | 94.6B | 99.14B |
| Total Equity | 140.03B | 156.61B | 183.83B | 215.08B | 247.04B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 19.04B | 20.01B | 27.25B | 30.92B | 34.25B |
| Investing | -9.41B | -10.24B | -16.41B | -13.18B | -16.32B |
| Financing | -1.6B | -2.35B | 3.47B | -16.2B | -13.78B |
| Market Cap | 4.67B |
| Price to Earnings Ratio | 0.15 |
| Price to Sales Ratio | 0.02 |
| Price to Cash Ratio | 0.05 |
| Price to Book Ratio | 0.02 |
| Dividend Yield | - |
| Shares Outstanding | 228.14M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -6.46% |
| 52 Week High | 26.72 |
| 52 Week Low | 20.49 |
| Spread (Intraday) | 105.01 (88.14%) |
| Company Name | Rohto Pharmaceutical Company (PK) |
| Address |
1 - 8-1 tatsuminish osaka, osaka 544-8666 |
| Website | https://www.rohto.co.jp |
| Industry | drugs-health r&d/testing labs (H8) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
